Pacylex Pharmaceuticals CEO Presents Zelenirstat for Acute Myeloid Leukemia at the World Orphan Drug Congress

Edmonton, Alberta, Canada April 22, 2024. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company focused on the development of a new class of targeted therapies, N-myristoyltransferase inhibitors (NMTi) for the treatment of hematologic cancers and solid tumors. Today Pacylex announced that CEO Michael Weickert will present Phase 1 safety and efficacy results for zelenirstat and evidence suppo